Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
EN | CN

You are here:Home-Chemical Inhibitors & Agonists-Tyrosine Kinase-VEGFR-AL3810
AL3810

Chemical Structure : AL3810

CAS No.: 1058137-23-7

AL3810 (AL-3810;AL 3810;E-3810;E3810;Lucitanib)

Catalog No.: PC-35892Not For Human Use, Lab Use Only.

AL3810 (AL-3810, E-3810, Lucitanib) is a potent, orally bioavailable, multiple tyrosine kinases inhibitor, potently inhibits VEGFR1/2/3 (IC50=7-25 nM) and FGFR1/2/3 (IC50=17.5-235 nM), also inhibits CSF1R with IC50 of 5 nM.

Packing Price Stock Quantity
10 mg $158 In stock
25 mg $258 In stock
100 mg $598 In stock
200 mg Get quote
1 g Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

AL3810 (AL-3810, E-3810, Lucitanib) is a potent, orally bioavailable, multiple tyrosine kinases inhibitor, potently inhibits VEGFR1/2/3 (IC50=7-25 nM) and FGFR1/2/3 (IC50=17.5-235 nM), also inhibits CSF1R with IC50 of 5 nM.
AL3810 (AL-3810, E-3810, Lucitanib) shows some activity against PDGFR α and PDGFR β with 20 times lower potency, no significant activity against FGFR4 (IC50>1 uM).
AL3810 (AL-3810, E-3810, Lucitanib) causes dose-dependent inhibition of the ligand-dependent phosphorylation of VEGFR-2 and FGFR-1 in low nanomolar range in cellular assays, potently inhibits VEGF and bFGF-stimulated HUVEC proliferation with IC50 of 40-50 nM.
AL3810 (AL-3810, E-3810, Lucitanib) inhibits the growth of different human tumor xenografts in vivo.

Physicochemical Properties

M.Wt 443.503
Formula C26H25N3O4
Appearance Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide

References

1. Zhou Y, et al. J Cell Mol Med. 2012 Oct;16(10):2321-30.

2. Bello E, et al. Cancer Res. 2011 Feb 15;71(4):1396-405. doi: 10.1158/0008-5472.CAN-10-2700.

3. Xie Q, et al. Acta Pharmacol Sin. 2017 Nov;38(11):1533-1542.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: